30 closest matches · ranked by relevance
Breast Cancer
Primary: Maximum Change in LVEF at 3 Months — 1; -5 change in percent ejection fraction
Pregnancy Complications
Primary: Plasma Concentration Troponin I — 1.2; 1.2 ng/L — p=0.05
Cardiotoxicity · Risk Factor, Cardiovascular · Toxicity Due to Chemotherapy
Primary: Left Ventricular Ejection Fraction (LVEF) — 61.1; 59.0; 61.9; 58.4 percent
HER2 Positive Breast Cancer · Left Ventricular Function Systolic Dysfunction
Primary: Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function. — 27 Participants
Breast Cancer
Primary: LVEF Results — -8; -6 LVEF Percentage (%)
Breast Cancer
Primary: Pre-operative Concentration of NT-proBNP — 38.9; 32.2 pg/ml — p=0.714
Degradation of Top2b and Top2a in Human by Dexrazoxane · Time Course and Degradation of Top2b in Human by Dexrazoxane · Effects of Dexrazoxane on Healthy Human
Primary: Participants With 95% Reduction in Topoisomerase 2 b From Baseline — 0; 0; 0; 0 Participants
Breast Cancer
Primary: Global Longitudinal Strain — 19.2; -19.6; 21.4; -21.5 % deformation
Heart Failure
Primary: The Percentage of Individuals in Each Group With a Significant Decline in the LVEF. — 22; 9 Participants
Primary Biliary Cholangitis · Cardiovascular Abnormalities
Primary: The Incidence of Cardiac Events — 0; 0; 0; 0 Participants — p=0.001
Transthyretin (TTR) Amyloid Cardiomyopathy
Primary: Time to All-Cause Mortality: Cohort A — 58.7; 35.8 Months — p=0.0001
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8 · Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 · Clinical Stage I Esophageal Adenocarcinoma AJCC v8
Primary: Proportion of Participants With a Cardiac Event at 12 Months — 0.6818 proportion of participants
Cardiomyopathy
Primary: Change in Left Ventricular Ejection Fraction — 10.6 percentage of LVEF
Parkinson's Disease
Primary: Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI at Time of Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day)…
Transthyretin (TTR) Amyloid Cardiomyopathy
Primary: Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular-Related Hospitalizations — 8595; 5071 wins — p=0.0006
Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
Primary: Average Left-Ventricular Wall Thickness-Dimension Ratio Z-score (LVWT/Dz) — -0.1372; -0.0893; -0.2167; 0.3215 z-score — p=0.15
Breast Cancer
Primary: LVEF — 65.4; 64.7; 62.2 percentage of blood in left ventricle — p=<0.0005
Solid Tumors
Primary: Change in QTcF (QT Corrected According to Fridericia's Formula) — 3.32; 1.76; 1.84; 1.32 ms (Milliseconds)
Node Positive Breast Cancer
Primary: Cardiac MRI Parameters — 0; 0; 0; 0 number of patients
Cardiac Arrythmias
Primary: Tp-e — 69.5; 74.7 milliseconds
Parkinson's Disease · Hyperprolactinemia
Primary: Number of Participants With Fibrotic Valvular Heart Disease Per 10,000 Participant-Years of Follow-Up — 21; 21; NA; 52 Participants/10,000 Participant-Years
Healthy Volunteers
Primary: Change-from-baseline Mean Effect of P03277 on QT Interval Expressed as QTc According to Fridericia's Formula (∆QTcF) — 0.97; 5.05; 0.24; -0.11 milliseconds
Familial ATTR-CM (ATTRm-CM, or FAC) · Wild-type ATTR-CM (ATTRwt-CM)
Primary: Change in Diastolic Blood Pressure — -3.1; -3.3; -4.3; -2.6 mm Hg
Healthy
Primary: Slope of the Placebo-corrected Change From Baseline of Heart Rate at Rest and Plasma Concentration Between 0 to 10 Hours — 0.80; 5.46 beats/min
Cardiogenic Shock
Primary: Number of Participants With Episodes of Arrhythmia — 0; 1 Participants — p=1
Acute Myocardial Infarction
Primary: ECG-documented Ventricular Fibrillation or Symptomatic Sustained Ventricular Tachycardia (VT) — 25; 8; 3; 2 participants
Amyloidosis · Amyloid Cardiomyopathy · Transthyretin Amyloidosis
Primary: A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT…
Healthy
Primary: The Maximum Mean Difference Between Each Single Dose of Either a Low Dose or a High Dose of Nerandomilast and Placebo in QTcF Changes From Baseline Between 20 Min to 24…
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
COVID-19
Primary: Hospital Length of Stay (LOS) — 5; 10; 25 days